Delving into the Latest Updates on Werthenstein BioPharma GmbH with Synapse

概览

疾病领域	数量

肿瘤	2
内分泌与代谢疾病	1
感染	1

排名前五的药物类型	数量

单克隆抗体	3
小分子化药	1

排名前五的靶点	数量

FGFR1 x KLB	1
RSV F protein(呼吸道合胞病毒F蛋白)	1
LILRB2(白细胞免疫球蛋白样受体亚家族B成员2)	1
KRAS G12C(KRAS G12C突变)	1

关联

4

项与 Werthenstein BioPharma GmbH 相关的药物

Clesrovimab

靶点

RSV F protein

作用机制

呼吸道合胞病毒F蛋白抑制剂

在研机构

Merck Sharp & Dohme Corp. [+2]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

呼吸道合胞体病毒感染

非在研适应症

呼吸道感染

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

MK-1084

靶点

KRAS G12C

作用机制

KRAS G12C抑制剂

在研机构

Werthenstein BioPharma GmbH [+3]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

KRAS G12C突变非小细胞肺癌 [+3]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

MK-4830

靶点

LILRB2

作用机制

LILRB2抑制剂

在研机构

Merck Sharp & Dohme Corp. [+3]

原研机构

Agenus, Inc.

在研适应症

卵巢癌 [+6]

非在研适应症

结直肠癌 [+2]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

5

项与 Werthenstein BioPharma GmbH 相关的临床试验

CTR20222590 / Recruiting临床1期

一项评估MK-1084单药治疗以及联合治疗KRASG12C突变晚期实体瘤受试者的安全性、耐受性、PK和有效性的I期、开放性、多中心研究

主要目的为确定MK-1084在单药治疗和联合治疗时的安全性和耐受性

开始日期2023-01-12

申办/合作机构

默沙东研发（中国）有限公司

[+2]

CTR20222877 / Active, not recruiting临床1期

一项研究MK-4830单药治疗和与帕博利珠单抗联合治疗晚期实体瘤受试者的I期、开放性、多组、多中心研究

评估MK-4830联合帕博利珠单抗在中国晚期/转移性实体瘤受试者中的安全性和药代动力学特征。

开始日期2022-12-16

申办/合作机构

默沙东研发（中国）有限公司

[+2]

CTR20221857 / Active, not recruiting临床3期

一项评估MK-1654用于健康早产儿和足月儿保护效力和安全性的Ⅱb/Ⅲ期双盲、随机、安慰剂对照研究

根据给药后第1天到第150天发生呼吸道合胞病毒所致需就医的急性下呼吸道感染（包括门诊和住院患者）的发病率，来评估MK-1654与安慰剂相比的保护效力。根据受试者中出现不良事件的构成比，来评估MK-1654与安慰剂相比的安全性和耐受性。

开始日期2022-08-20

申办/合作机构

默沙东研发（中国）有限公司

[+2]

100 项与 Werthenstein BioPharma GmbH 相关的临床结果

登录后查看更多信息

0 项与 Werthenstein BioPharma GmbH 相关的专利（医药）

登录后查看更多信息

1

项与 Werthenstein BioPharma GmbH 相关的文献（医药）

2024-05-01·Biotechnology and Bioengineering

Robust platform for inline Raman monitoring and control of perfusion cell culture

Article

作者: Jayapal, Karthik ; Appiah-Amponsah, Emmanuel ; Zhou, George ; Patel, Bhumit ; Mueller, Marvin ; Bieri, Marco ; Wan, Boyong ; Patel, Misaal ; Olma, Michael

AbstractPerfusion cell culture has been gaining increasing popularity for biologics manufacturing due to benefits such as smaller footprint, increased productivity, consistent product quality and manufacturing flexibility, cost savings, and so forth. Process Analytics Technologies tools are highly desirable for effective monitoring and control of long‐running perfusion processes. Raman has been widely investigated for monitoring and control of traditional fed batch cell culture process. However, implementation of Raman for perfusion cell culture has been very limited mainly due to challenges with high‐cell density and long running times during perfusion which cause extremely high fluorescence interference to Raman spectra and consequently it is exceedingly difficult to develop robust chemometrics models. In this work, a platform based on Raman measurement of permeate has been proposed for effective analysis of perfusion process. It has been demonstrated that this platform can effectively circumvent the fluorescence interference issue while providing rich and timely information about perfusion dynamics to enable efficient process monitoring and robust bioreactor feed control. With the highly consistent spectral data from cell‐free sample matrix, development of chemometrics models can be greatly facilitated. Based on this platform, Raman models have been developed for good measurement of several analytes including glucose, lactate, glutamine, glutamate, and permeate titer. Performance of Raman models developed this way has been systematically evaluated and the models have shown good robustness against changes in perfusion scale and variations in permeate flowrate; thus models developed from small lab scale can be directly transferred for implementation in much larger scale of perfusion. With demonstrated robustness, this platform provides a reliable approach for automated glucose feed control in perfusion bioreactors. Glucose model developed from small lab scale has been successfully implemented for automated continuous glucose feed control of perfusion cell culture at much larger scale.

100 项与 Werthenstein BioPharma GmbH 相关的药物交易

登录后查看更多信息

100 项与 Werthenstein BioPharma GmbH 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

2

1

临床2期

临床3期

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Clesrovimab ( RSV F protein )	-	临床3期
NGM-313 ( FGFR1 x KLB )	非酒精性脂肪性肝炎更多	临床2期
MK-1084 ( KRAS G12C )	KRAS G12C突变的实体瘤更多	临床1期
MK-4830 ( LILRB2 )	晚期恶性实体瘤更多	临床1期